Spatiotemporally precise optogenetic activation of sensory neurons in freely walking Drosophila
Abstract
Previous work has characterized how walking Drosophila coordinate the movements of individual limbs (DeAngelis, Zavatone-Veth, and Clark, 2019). To understand the circuit basis of this coordination, one must characterize how sensory feedback from each limb affects walking behavior. However, it has remained difficult to manipulate neural activity in individual limbs of freely moving animals. Here, we demonstrate a simple method for optogenetic stimulation with body side-, body segment-, and limb-specificity that does not require real-time tracking. Instead, we activate at random, precise locations in time and space and use post hoc analysis to determine behavioral responses to specific activations. Using this method, we have characterized limb coordination and walking behavior in response to transient activation of mechanosensitive bristle neurons and sweet-sensing chemoreceptor neurons. Our findings reveal that activating these neurons has opposite effects on turning, and that activations in different limbs and body regions produce distinct behaviors.
Data availability
Source data were deposited on Dryad: https://doi.org/10.5061/dryad.nzs7h44nk.Analysis code is available here: https://github.com/ClarkLabCode/FlyLimbOptoCode.
-
Data from: Spatiotemporally precise optogenetic activation of sensory neurons in freely walking <em>Drosophila</em>Dryad Digital Repository, 10.5061/dryad.nzs7h44nk.
Article and author information
Author details
Funding
National Institutes of Health (EY026555)
- Brian D DeAngelis
- Damon A Clark
National Institutes of Health (EY026878)
- Brian D DeAngelis
- Damon A Clark
Chicago Community Trust (Searle Scholar Award)
- Damon A Clark
Alfred P. Sloan Foundation (Fellowship)
- Damon A Clark
National Science Foundation (GRF)
- Brian D DeAngelis
Smith Family Foundation (Scholar Award)
- Brian D DeAngelis
- Damon A Clark
National Science Foundation (IOS 1558103)
- Jacob A Zavatone-Veth
- Damon A Clark
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Ronald L Calabrese, Emory University, United States
Version history
- Received: December 12, 2019
- Accepted: April 21, 2020
- Accepted Manuscript published: April 22, 2020 (version 1)
- Version of Record published: May 4, 2020 (version 2)
Copyright
© 2020, DeAngelis et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,142
- views
-
- 370
- downloads
-
- 6
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Neuroscience
Improving our understanding of autism, ADHD, dyslexia and other neurodevelopmental conditions requires collaborations between genetics, psychiatry, the social sciences and other fields of research.
-
- Genetics and Genomics
- Neuroscience
Genome-wide association studies have revealed >270 loci associated with schizophrenia risk, yet these genetic factors do not seem to be sufficient to fully explain the molecular determinants behind this psychiatric condition. Epigenetic marks such as post-translational histone modifications remain largely plastic during development and adulthood, allowing a dynamic impact of environmental factors, including antipsychotic medications, on access to genes and regulatory elements. However, few studies so far have profiled cell-specific genome-wide histone modifications in postmortem brain samples from schizophrenia subjects, or the effect of antipsychotic treatment on such epigenetic marks. Here, we conducted ChIP-seq analyses focusing on histone marks indicative of active enhancers (H3K27ac) and active promoters (H3K4me3), alongside RNA-seq, using frontal cortex samples from antipsychotic-free (AF) and antipsychotic-treated (AT) individuals with schizophrenia, as well as individually matched controls (n=58). Schizophrenia subjects exhibited thousands of neuronal and non-neuronal epigenetic differences at regions that included several susceptibility genetic loci, such as NRG1, DISC1, and DRD3. By analyzing the AF and AT cohorts separately, we identified schizophrenia-associated alterations in specific transcription factors, their regulatees, and epigenomic and transcriptomic features that were reversed by antipsychotic treatment; as well as those that represented a consequence of antipsychotic medication rather than a hallmark of schizophrenia in postmortem human brain samples. Notably, we also found that the effect of age on epigenomic landscapes was more pronounced in frontal cortex of AT-schizophrenics, as compared to AF-schizophrenics and controls. Together, these data provide important evidence of epigenetic alterations in the frontal cortex of individuals with schizophrenia, and remark for the first time on the impact of age and antipsychotic treatment on chromatin organization.